Treatment of Renal Stones With Frankincense (Luban)
Status:
Unknown status
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
Frankincense, or olibanum, is the oleogum resin that is harvested from several different
trees, an aromatic resin obtained from trees of the genus Boswellia. The word frankincense is
derived from the ancient French name "frankincense," meaning "pure incense." Frankincense is
also known in Arabic as "luban,". Luban has been reported to have anti-inflammatory,
sedative, antibacterial, and anti-cancer activities. The aim of the present study is to treat
renal stones with Luban (Boswellia) given as capsules of active oils.
This is a clinical Phase I & II (Safety, Efficacy) double-blind simple-randomized controlled
treatment trial, where 100 participants with renal stones (50 Radiopaque and 50 Radiolucent
stones) will be included in the study and divided between two treatment groups: Standard
treatment (Uralyt-U) and new treatment (Luban). Participants with stone size less than 10 mm
will be include; and participants with renal pathology or comorbidities (DM, CKD, multiple
renal cysts, renal tumors) will be excluded. The outcome measures of the study will be: the
primary end point (effect) is reduction of stone size by 50% or complete disappearance after
1 years of treatment; and the secondary end point (toxicity) is the participants intolerance
of the treatment or development of side effects. If this study proves an effect of Luban on
renal stones it will be an evolution in the management of renal stones by a natural, simple,
harmless easily available method.